Characterization of three monoclonal antibodies against C3 with selective specificities. 1987

K Iida, and K Mitomo, and T Fujita, and N Tamura
Department of Immunology, University of Tsukuba, Ibaraki, Japan.

We raised 15 mouse monoclonal antibodies against human C3 from two separate fusions. Mouse plasmacytoma cells were fused with spleen cells from mice immunized either with a mixture of C3, C3b and C3c, or with a mixture of C3dg and C3d. Three of the 15 monoclonals were characterized in detail. N-7A reacted with native C3 as well as C3b and C3c. Two other monoclonals, C-5G and G-3E, recognized neoantigenic determinants on C3c and C3dg, respectively. In ELISA, C-5G reacted with C3b and C3c but not with native C3 nor with C3dg; and on the other hand G-3E reacted only with C3dg. The selective specificities of these monoclonals were further confirmed in a binding assay to C3 fragments formed on cellular intermediates. C-5G bound exclusively to EC3b, and G-3E bound to EiC3b, EC3dg and EC3d. N-7A bound only very poorly to EC3b. C-5G inhibited both the haemolytic activity of C5 convertase and also the CR1-mediated rosette formation of B-enriched peripheral mononuclear cells with EC3b. G-3E inhibited the CR2-mediated EC3dg-rosette formation of Raji cells. These monoclonals, with selective specificities, can distinguish the state of activation and degradation of the C3 molecule.

UI MeSH Term Description Entries
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D012397 Rosette Formation The in vitro formation of clusters consisting of a cell (usually a lymphocyte) surrounded by antigenic cells or antigen-bearing particles (usually erythrocytes, which may or may not be coated with antibody or antibody and complement). The rosette-forming cell may be an antibody-forming cell, a memory cell, a T-cell, a cell bearing surface cytophilic antibodies, or a monocyte possessing Fc receptors. Rosette formation can be used to identify specific populations of these cells. Immunocytoadherence,Formation, Rosette,Formations, Rosette,Immunocytoadherences,Rosette Formations
D050577 Complement C3-C5 Convertases Serine proteases that cleave COMPLEMENT C3 into COMPLEMENT C3A and COMPLEMENT C3B, or cleave COMPLEMENT C5 into COMPLEMENT C5A and COMPLEMENT C5B. These include the different forms of C3/C5 convertases in the classical and the alternative pathways of COMPLEMENT ACTIVATION. Both cleavages take place at the C-terminal of an ARGININE residue. C3 Convertase,C 3 Convertase,C3 Activator,C3-C5 Convertase,C5 Cleaving Enzyme,C5 Convertase,Complement 3 Convertase,Complement 5 Convertase,Complement C3 Convertases,Complement C5 Convertases,Activator, C3,C3 C5 Convertase,C3 Convertases, Complement,C3-C5 Convertases, Complement,C5 Convertases, Complement,Complement C3 C5 Convertases,Convertase, C 3,Convertase, C3,Convertase, C3-C5,Convertase, Complement 3,Convertases, Complement C3,Convertases, Complement C3-C5,Convertases, Complement C5

Related Publications

K Iida, and K Mitomo, and T Fujita, and N Tamura
August 1984, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
K Iida, and K Mitomo, and T Fujita, and N Tamura
November 1980, Immunology,
K Iida, and K Mitomo, and T Fujita, and N Tamura
April 1992, European journal of immunology,
K Iida, and K Mitomo, and T Fujita, and N Tamura
January 1994, Gynecologic and obstetric investigation,
K Iida, and K Mitomo, and T Fujita, and N Tamura
January 1990, Complement and inflammation,
K Iida, and K Mitomo, and T Fujita, and N Tamura
January 1986, Infection and immunity,
K Iida, and K Mitomo, and T Fujita, and N Tamura
October 1984, Molecular immunology,
K Iida, and K Mitomo, and T Fujita, and N Tamura
October 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy,
K Iida, and K Mitomo, and T Fujita, and N Tamura
March 1982, Journal of immunology (Baltimore, Md. : 1950),
K Iida, and K Mitomo, and T Fujita, and N Tamura
December 1982, Molecular immunology,
Copied contents to your clipboard!